News

Gynecologic Cancers

Risovalisib Yields Highest Reported Monotherapy Response Rate in Ovarian Clear Cell Carcinoma

November 18 2 min read
In a phase II trial, risovalisib yielded a 35% objective response rate in patients with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma.

Latest in News